Vivet Therapeutics to Present Key Findings on its Gene Therapy Program for Cerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting
14 nov. 2024 03h30 HE
|
Vivet Therapeutics
Vivet Therapeutics to Present Key Findings on its Gene Therapy Program for Cerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting Gene therapy...
Bioxodes annonce la recommandation positive du DMC pour son essai de phase 2a dans le traitement des AVC hémorragiques avec BIOX-101
21 août 2024 02h30 HE
|
Bioxodes
Le Comité de surveillance des données (DMC, Data Monitoring Committee) a recommandé la poursuite de l’étude après l’examen planifié des données provenant des 8 premiers patients L’analyse des...
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
21 août 2024 02h30 HE
|
Bioxodes
Planned Data Monitoring Committee (DMC) meeting recommended continuation of the study after reviewing data from the first 8 patients Interim data from 16 patients scheduled around the end of 2024 ...
Release Therapeutics Secures CHF 3.3 Million in Seed Funding
06 août 2024 04h00 HE
|
Release Therapeutics SA
Release Therapeutics Secures CHF 3.3 Million in Seed Funding following first preclinical results in metachromatic leukodystrophy.
Bioxodes franchit une première étape dans le recrutement de patients pour son essai de phase 2a dans le traitement des hémorragies intracérébrales avec BIOX-101
27 juin 2024 02h30 HE
|
Bioxodes
Candidat médicament « first-in-class » évalué chez les huit premiers patients Gosselies (Belgique), le 27 juin 2024 – Bioxodes SA, société biopharmaceutique en phase clinique développant de...
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke
27 juin 2024 02h30 HE
|
Bioxodes
First-in-class drug candidate evaluated in first eight patients Gosselies (Belgium), June 27, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for...
L'Office européen des brevets notifie Bioxodes de son intention de délivrer un brevet offrant une large protection à son actif principal dans le traitement des thrombo-inflammations
16 mai 2024 03h04 HE
|
Bioxodes
Gosselies (Belgique), le 16 mai 2024 – Bioxodes SA, société biopharmaceutique de stade clinique développant de nouvelles thérapies dédiées à la prévention et au traitement de maladies thrombotiques et...
Bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflammation
16 mai 2024 03h04 HE
|
Bioxodes
Gosselies (Belgium), May 16, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases,...
USD 44 Bn Medical Foods Market to Grow at a CAGR of 7.5% During 2023 to 2031 | Transparency Market Research
29 mars 2023 15h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, March 30, 2023 (GLOBE NEWSWIRE) -- According to market research conducted by TMR, the global medical foods industry was valued at USD 23.0 Bn in 2022 and is...
AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH
07 mars 2023 03h00 HE
|
AB2 Bio Ltd
Topline pivotal Phase 3 results expected during second half of 2023Potential new treatment option in ultra-rare, life-threatening, primarily pediatric disease with no approved therapies Lausanne...